Lipid Nanocapsules: A Nanocarrier Suitable for Scale-Up Process

https://doi.org/10.1016/S1773-2247(13)50084-0Get rights and content

Nanomedicine is a great hope to enhance the efficacy of drugs and thus the health of many. Unfortunately, while nanotechnology is not new, industrial processing is a major barrier for the market access of nanomedicines. The aim of this work was to study the scale-up possibilities for a very promising formulation; i.e., lipid nanocapsules (LNCs) developed in our laboratory. Pilot-scale batches of ibuprofen LNCs and free-drug LNCs (50 x scale factor) were compared to lab-scale batches. Average diameter, zeta potential and drug loading were determined at the pilot and lab scales. Stability was also studied over time at 4 °C and room temperature by monitoring size, drug loading and zeta potential over 12 months. It was found that average diameter, zeta potential and drug loading were not significantly different for the pilot and lab scale (p < 0.05). After scale-up, the entrapment efficiency of ibuprofen remained over 97 % and the polydispersity index remained very low (< 0.03). The stability study showed a slight increase of LNC diameter along time and a decrease of zeta potential only for free-drug LNCs. In the case of ibuprofen-loaded LNCs, drug loading remained over 96 % throughout the study at 4 °C and room temperature. These results showed the good ability of LNCs for scale-up without any complex optimization processes. This makes LNCs good candidates for industrial processing and market access.

References (0)

Cited by (34)

  • Lipid nanocapsules for intracellular delivery of microRNA: A first step towards intervertebral disc degeneration therapy

    2022, International Journal of Pharmaceutics
    Citation Excerpt :

    Therefore, compared with liposomes formulated by a process involving organic solvents and known to be unstable in biological fluids, LNC are more promising from an industrial perspective because they are prepared using a solvent-free, soft-energy procedure, and the excipients used are free of genetically modified organism and approved by the US Food and Drug Administration (FDA) (Hureaux et al., 2010). Furthermore, the industrial scale-up of LNC was previously investigated and an easy scalability of production was noted (Thomas and Lagarce, 2013). These features indicate that miR LNC have ample potential as candidates for industrial production and commercialization (Tsirimonaki et al., 2013).

  • Formulation development and upscaling of lipid nanocapsules as a drug delivery system for a novel cyclic GMP analogue intended for retinal drug delivery

    2021, International Journal of Pharmaceutics
    Citation Excerpt :

    Lipid nanocapsules (LNCs) are nanoparticles prepared by a solvent-free, low-energy phase inversion method (Hirsjärvi et al., 2013; Huynh et al., 2009; Thomas and Lagarce, 2013; Valcourt et al., 2016), and consist of an oily core composed of medium chain triglycerides which is enveloped by a layer of hydrophilic and hydrophobic surfactants (Heurtault et al., 2002; Mouzouvi et al., 2017; Valcourt et al., 2016).

View all citing articles on Scopus
View full text